OBJECTIVE: The objective of this study was to evaluate the association between microsatellite instability (MSI) status and (1) ovarian cancer risk factors and (2) the distribution of the specific histologic subtypes in a population-based sample of epithelial ovarian cancers. METHODS: Participants were drawn from 3 population-based studies of primary epithelial ovarian cancer. Tumor DNA was analyzed using 5 standardized microsatellite markers to assess MSI status. Patients were divided into 3 groups (MSI-high, MSI-low, and MSI-stable) according to National Cancer Institute criteria. We compared the prevalence of specific known risk and protective factors among the 3 subgroups, including body mass index, smoking history, parity, BRCA1 and BRCA2 mutation status, past oral contraceptive use, and tubal ligation. Similarly, we compared the distribution of the histologic subtypes among the 3 subgroups. RESULTS: A total of 917 ovarian cancer patients were included. One hundred twenty-seven (13.8%) cancers were MSI-high. Subgroup analyses according to smoking, body mass index, parity, past oral contraceptive use, and past tubal ligation did not reveal any statistically significant differences among the groups. Among the 29 patients with BRCA1 mutations, 20.7% had MSI-high cancers compared with 5.9% among 17 BRCA2-mutation patients. The proportions of different ovarian cancer histologic findings among the various MSI subgroups were similar. CONCLUSIONS: The prevalence of risk and protective factors among ovarian cancer patients is similar for cancers with and without MSI. The distributions of MSI do not differ significantly among ovarian cancers with different histologic findings. Ovarian cancer patients with BRCA1 mutations had a 21% rate of MSI-high tumors, compared with 6% among patients with BRCA2 mutations, but this difference was not statistically significant.
OBJECTIVE: The objective of this study was to evaluate the association between microsatellite instability (MSI) status and (1) ovarian cancer risk factors and (2) the distribution of the specific histologic subtypes in a population-based sample of epithelial ovarian cancers. METHODS:Participants were drawn from 3 population-based studies of primary epithelial ovarian cancer. Tumor DNA was analyzed using 5 standardized microsatellite markers to assess MSI status. Patients were divided into 3 groups (MSI-high, MSI-low, and MSI-stable) according to National Cancer Institute criteria. We compared the prevalence of specific known risk and protective factors among the 3 subgroups, including body mass index, smoking history, parity, BRCA1 and BRCA2 mutation status, past oral contraceptive use, and tubal ligation. Similarly, we compared the distribution of the histologic subtypes among the 3 subgroups. RESULTS: A total of 917 ovarian cancerpatients were included. One hundred twenty-seven (13.8%) cancers were MSI-high. Subgroup analyses according to smoking, body mass index, parity, past oral contraceptive use, and past tubal ligation did not reveal any statistically significant differences among the groups. Among the 29 patients with BRCA1 mutations, 20.7% had MSI-high cancers compared with 5.9% among 17 BRCA2-mutation patients. The proportions of different ovarian cancer histologic findings among the various MSI subgroups were similar. CONCLUSIONS: The prevalence of risk and protective factors among ovarian cancerpatients is similar for cancers with and without MSI. The distributions of MSI do not differ significantly among ovarian cancers with different histologic findings. Ovarian cancerpatients with BRCA1 mutations had a 21% rate of MSI-high tumors, compared with 6% among patients with BRCA2 mutations, but this difference was not statistically significant.
Authors: Jaya M Satagopan; Jeff Boyd; Noah D Kauff; Mark Robson; Lauren Scheuer; Steven Narod; Kenneth Offit Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: S A Narod; P Sun; P Ghadirian; H Lynch; C Isaacs; J Garber; B Weber; B Karlan; D Fishman; B Rosen; N Tung; S L Neuhausen Journal: Lancet Date: 2001-05-12 Impact factor: 79.321
Authors: H A Risch; J R McLaughlin; D E Cole; B Rosen; L Bradley; E Kwan; E Jack; D J Vesprini; G Kuperstein; J L Abrahamson; I Fan; B Wong; S A Narod Journal: Am J Hum Genet Date: 2001-02-15 Impact factor: 11.025
Authors: Robert M Wenham; Joellen M Schildkraut; Kia McLean; Brian Calingaert; Rex C Bentley; Jeffrey Marks; Andrew Berchuck Journal: Clin Cancer Res Date: 2003-10-01 Impact factor: 12.531
Authors: Athanassios Dellas; Alex Puhl; Peter Schraml; Sabine E Thomke; Josef Rüschoff; Michael J Mihatsch; Holger Moch Journal: Anticancer Res Date: 2004 Jan-Feb Impact factor: 2.480
Authors: R Parsons; G M Li; M J Longley; W H Fang; N Papadopoulos; J Jen; A de la Chapelle; K W Kinzler; B Vogelstein; P Modrich Journal: Cell Date: 1993-12-17 Impact factor: 41.582
Authors: T Pal; M R Akbari; P Sun; J-H Lee; J Fulp; Z Thompson; D Coppola; S Nicosia; T A Sellers; J McLaughlin; H A Risch; B Rosen; P Shaw; J Schildkraut; S A Narod Journal: Br J Cancer Date: 2012-10-09 Impact factor: 7.640